Goldman Sachs Group Inc Nu Cana PLC Transaction History

Goldman Sachs Group Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.74 - $3.27 $37,704 - $166,613	-50,952 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.02 - $2.9 $67,663 - $97,141	33,497 Added 191.9%	50,952 $121,000
Q3 2021 Nov 10, 2021	BUY	$1.95 - $2.85 $34,037 - $49,746	17,455 New	17,455 $45,000

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $64.2M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.